Publications

Names followed by * indicate student status at the time of publication

Poloyac SM, Perez A, Scheff S, and Blouin RA. Tissue Specific Alterations in CYP2E1 Expression Following Traumatic Brain Injury in the Rat. Drug Metab Dispos 2001; 29(3

Fabian TJ*, Dew MA, Pollock BG, Reynolds CF, Mulsant BH, Butters MA, Zmuda MD, Linares AM, Trottini M, and Kroboth PD.  Endogenous Concentrations of DHEA and DHEA-S Decrease with Remission of Depression in Older Adults.  Biological Psychiatry 2001; 50(10); 767-774.

Kroboth PD, Folan MM, Kroboth FJ, Haas GL, Stone RA, Linares AM, Erosheva E, Frye RF, Sweeney JA, The influence of an oral dose of alprazolam on DHEA concentrations in men and women. Society of Nueroscience 1999;25:2228.

Folan MM, Stone RA, Pittenger AL, Stoffel J, Hess MM, and Kroboth PD.  DHEA, DHEA-S, and cortisol concentrations in intensive care unit patients.  Critical Care Medicine 2001; 29(5):965-970.

Blyth BJ, Hauger RL, Purdy RH, and Amico JA. The neurosteroid allopregnanolone modulates ovarian steroid-mediated increases in oxytocin expression in the hypothalamic paraventricular nucleus of the rat.  Am J Physiol Regulatory, Integrative, Comp Physiol 2000; 278:R684-R691.

Amico JA, Davis AM, and McCarthy MM.  An ovarian steroid regimen that increases hypothalamic oxytocin expression alters [3H]muscimol binding in the hypothalamic supraoptic nucleus of the female rat. Brain Research 2000; 857:279-282.

Marar I.E, Mulsant BH, Towers A, Pollock BG, and Amico JA.  The effect of    

paroxetine on   plasma vasopressin and water load testing in elderly subjects.  J of Geriatric Psychiatry and Neurology 2000; 13:212-216.

Light  KC, Smith TE, Johns JM, Hofheimer JA, and Amico JA.  Oxytocin responsivity in mothers of infants: a preliminary study of relationships with blood pressure during laboratory stress and normal ambulatory activity.  Health Psychology 2000; 19:560-567.

Brown DC, Perkowski SC, Amico JA.  Effect of centrally administered opioid receptor agonists on central and peripheral oxytocin activity in the dog  Am Journal of Veterinary Research  2001; 62(4):496-499.

Mantella RC, Vollmer RR, Li X, and Amico JA.   Female oxytocin deficient mice display enhanced anxiety like behavior.  Endocrinology 2003; 144:2291-2296.

Michelini LC, Marcelo MC, Amico JA, and Morris M.  Oxytocinergic regulation of cardiovascular function: studies in oxytocin gene deletion mice.  Am J Physiol Heart and Circulatory Physiology   2003; 284:H2269-H2279.

Amico  JA, Morris M, and Vollmer RR.  Mice deficient in oxytocin manifest increases in saline consumption following overnight water deprivation.  Am J Physiol.Regulatory, Integrative, Comp Physiol  2001; 281:R1368-R1373.

Puryear  R, Rigatto K, Amico JA, and Morris M.  Enhanced salt appetite in an oxytocin gene deletion model.  Experimental Neurology  2001; 171:323-328.

Amico JA, Cai HM, Rauk P  Estrogen and progesterone regulation of oxytocin receptor binding and expression in human breast cancer cell lines  Endocrine 2002; 18:79-84.

Turner RA, Altemus M,  Bostrom A, Lyons D, and Amico JA.  Effects of positive and negative emotion on oxytocin, prolactin, and ACTH in women.  Stress 2002; 5:269-276.    

Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, and Frye RF.  Application of   semisimultaneous midazolam administration for hepatic and intestinal CYP 3A   

Phenotyping. Clinical Pharmacology and Therapeutics 2002; 72:718-728

Amico JA, *Mantella RC, and Vollmer, RR.  Consumption of solutions containing sodium chloride  is enhanced in female oxytocin deficient mice.  Behavioral Neuroscience 2003; 117(1):32-37.

Erosheva, E.A., Salek FS, Stone RA, Folan MM, Greenhouse J, Kroboth PD. Characterizing the diurnal rythm of DHEA and effects of an oral does of alprazolam. Biol.Psychiatry 1999;47;145S.

Kroboth PD, Amico JA, Stone RA, Folan MM, Frye RF, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C. Influence of DHEA Administration on 24-Hour Cortisol Concentrations. J Clin Psychopharmacol. 2003;23: 96-99.

Mantella RC, Rinamann L, Vollmer RR, and Amico JA.  Cholecystokinin and D-fenfluramine inhibit food intake in oxytocin deficient mice.  Am J Physiol Regulatory, Integrative, Comp Physiol  2003; 285:R1037-R1045.

Amico JA,  Mantella RC*, Vollmer RR, Li X, and Cai HM.  Anxiety and stress responses in female oxytocin deficient mice.  J of Neuroendocrinology  2004; 16:319-324.

Amico JA, Volmer RR, Karam JR*, Lee PR, LI X, Koenig JI, and McCarthy MM.  Centrally administered oxytocin elicits exaggerated grooming  in oxytocin null mice.  Pharmacology, Biochemistry and Behavior 2004; 78:333-338.

Augustine, JA* and Zemaitis MA.  The effects of cyclosporin-A (CsA) on hepatic microsomal drug metabolism in the rat.  Drug Metab Disp 1986; 14:73-78.

McKelvey JA* and Zemaitis MA.  The effects of ethylene oxide (EO) exposure on tissue glutathione levels in rats and mice.  Drug and Chem Toxicol 1986; 9:51-56.

Peffer RC, Abraham DJ, Zemaitis MA, Wong LK, and Alvin JD.  3,4-Dichlorobenzyloxyacetic acid is extensively metabolized to a taurine conjugate in rats.  Drug Metab Disp 1987; 15:305-311.

D'Souza MJ, Zemaitis MA, Burckart GJ, and Venkataramanan R.  A simple high-performance liquid chromatographic method for simultaneous determination of aminopyrine and its metabolites.  J Chromatogr 1987; 421:198-205.

Venkataramanan R, Warty VS, Zemaitis MA, Sanghvi AT, Burckart GJ, Seltman H, Todo S, Makowka L, and Starzl TE.  Biopharmaceutical aspects of FK-506.  Transpl Proc 1987; 19:30-35.

Augustine JA* and Zemaitis MA.  A comparison of the effects of cyclosporine (CsA) on hepatic microsomal drug metabolism in three different strains of rats.  General Pharmacol 1989; 20(2):137-141.

Stiff DD* and Zemaitis MA.  Metabolism of the anticonvulsant agent zonisamide in the rat.  Drug Metab Disp 1990; 18:888-894.

Schmith VD, Cox SR, Zemaitis MA, and Kroboth PD.  A new HPLC method for analysis of alprazolam and its metabolites in serum:  instability of 4-hydroxyalprazolam.  J Chromatog B: Biomed Appl 1991; 568:253-260.

Stiff DD*, Robicheau JT, and Zemaitis MA.  Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative.  Xenobiotica 1992; 22:1-11.

Prasad TNV, Stiff DD*, Subbotina N, Zemaitis MA, Burckart GJ, Starzl TE, and Venkataramanan R. FK-506 (Tacrolimus) metabolism by rat liver microsomes as a predictor of its inhibition by other drugs. Res Comm Chem Path Pharmacol 1994; 84:35-46.

Minnigh MB, Alvin JD, and Zemaitis MA. Determination of plasma mexiletine levels with gas chromatography-mass spectrometry and selected ion  monitoring.  J Chromatog B: Biomed Appl 1994; 662: 118-122.

Lopez, JA, Barillas W, Gomez-Lautiro J, Martin GE, Al-Rehaily AJ, Zemaitis MA, and Schiff PL. Granulosin, a new chromone from Galipea granulosa. J Natural Prod 1997; 60:24-26.

Lopez JA, Barillas W, Gomez-Lautiro J, Martin GE, Al-Rehaily AJ, Zemaitis MA, and Schiff PL.  Galiposin, a new B-hydroxychalcone from Galipea granulosa. Planta Med 1998; 64:76-77.

Al-Rehaily AJ, Gao C, Martin GE, Lin F, Zemaitis MA, and Schiff PL. Thalpetaline, A new alkaloid of Thalictrum petaloideum var. supradecompositum. Planta Med 1998; 64:681.

Dowling TC, Frye RF, and Zemaitis MA. Simultaneous determination of p-aminohippuric acid and iothamlate in human plasma and urine by high-performance liquid chromatography.  J Chromatog B: Biomed Appl 1998; 716:305-313.

Al-Rehaily AJ, Sharaf MHM, Zemaitis MA, Gao C, Martin GE, Hadden CE, Thamann TJ, Lin F, and Schiff PL. Thalprzewalskiinone, a new oxybenzylisoquinoline alkaloid from Thalictrum przewalskii. J Natural Prod 1999; 62(1):146-148.

Al-Howiriny, T.A., Zemaitis, M.A., Gao, C., Hadden, C.E., Martin, G.E., Lin, F. and Schiff, P.L.: Thalibealine, A novel tetrahydroprotoberberine-aporphine dimeric alkaloid from Thalictrum wangii. J Natural Prod 64(6):819-822 (2001).

Al-Howirin, TA, Zemaitis MA, Gao C, Hadden CE, Martin GE, Lin F, and Schiff PL.  The synthesis of thalprzewalskiinone, a revision of structure. J Natural Prod 2001; 64(6):823-826.

Al-Howiriny TA, Zemaitis MA, Lin F, and Schiff PL.  Alkaloids of Thalictrum augustifolium. J.  Herbal Pharmacotherapy 2002; 2(2): 1-10.

Zemaitis MA, Poloyac SM, and Frye RF. Identification of omega hydroxy fatty acids in biological samples as their pentafluoropropyl-derivatives with positive and negative electron impact gas chromatography-mass spectrometry.  Rapid Com Mass Spectrom 2002; 16 (15): 1411-1415.

Bolcato CA*, Zemaitis MA, Frye RF, and Poloyac SM.  Determination of 20-hydroxyeicosatetraneoic acid (20-HETE) in microsomal incubations using high performance liquid chromatography-mass spectrometry.  J Chromatog B 2003; 794: 363-372.

Poloyac SM, Tortorici M, Przychodzin DI, Reynolds RB, Xie W, Frye RF, and Zemaitis MA.  The Effect of Isoniazid on CYP2E1 and CYP4A Mediated Hydroxylation of Arachidonic Acid in the Rat Liver and Kidney.  Drug Metab Dispos. 2004; 32(7): 727-733.

Xie W, Uppal H, Saini S, Mu Y, Little J, Radominska-Pandya A and Zemaitis M.  Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism and human diseases.  Drug Discovery Today  2004; 9(10): 442-449.

Reichman SE, Fabian TJ, Kroboth PD, and Ferrell RE.  Steroid Sulfatase Gene Variation and DHEA responsiveness to resistance exercise in MERET. Physiological Genomics 2004; 17:300-306.

Kobert LJ, Folan MM.  Coming of age in nursing:  rethinking the philosophies behind holism and nursing process.  Journal: Nursing & Health Care 1990; 11(6):308-312.

Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: A review of clinical studies. J Clin Pharmacol 2002;42(3) 247-266.

Bonate PL, Kroboth PD, Smith RB, Suarez E, Oo C. Clonazepam and Sertraline: Absence of a Drug Interaction in a Multiple Dose Study. J Clin Psychopharmacol 2000; 20 (1): 1-9.

Poloyac SM Gardner BM, Tosheva RT, Shedlofsky SI, and Blouin RA. The Effect of Endotoxin Administration on the Pharmacokinetics of Chlorzoxazone in Humans. In Press, Clin Pharmacol Ther 1999; 66(6): 554-562.

Warren GW, Poloyac SM Gary DS, Mattson MP, and Blouin RA. Hepatic Cytochrome P450 Expression in TNF a (p55, p75) Receptor Knockout Mice Following Endotoxin Administration. J Pharmacol Exp Ther 1999; 288 (3): 945-50.

Watson A, Poloyac SM, and Blouin RA. The Effect Of Leptin Administration on the Expression of Drug Metabolizing Enzymes. Drug Metab Disp 1999; 27(6): 695-700.

Lu M, Poloyac SM, Blouin RA. Evaluation of Formation Clearance of Dapsone Hydroxylamine as a Marker of CYP3A Activity: an In Vivo And In Vitro Correlation. J Pharm Pharmacol 1999; 51: 803-10.

Kroboth PD, Salek FS*, Stone R, Bertz RJ*, Kroboth FJ. Alprazolam increases dehydroepiandrosterone concentrations. J Clin Psychopharmacol. 1999; 19: 114-124.

Kroboth PD, Bertz RJ*, Salek FS*, Marcuson D*. Detecting and studying acute tolerance using pharmacodynamics. Lead Article for Clinical Pharmacokinetics; manuscript drafted.

Zemaitis MA, Kroboth PD. Simplified procedure for measurement of dehydroepiandrosterone and its sulfate with gas chromatography - ion trap mass spectrometry and selected reaction monitoring. J Chromatography B. 1998; 716: 19-26.

Kroboth PD, McAuley JW*. Progesterone: Does it affect response to drug- Psychopharmacology Bulletin 1997; 33(2): 297-301.

Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, and Condifer KA.  Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women.  J Clin Pharmacol 1999; 39(9):936-940.

Gleason PP, Schulz R, Smith NL, Newsom JT, Kroboth PD, Kroboth FJ, Psaty BM. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Int Med 1998; 13:243-250.

Sweeney JA, Bauer KS*, Keshavan MS, Haas GL, Schooler NR, Kroboth PD. Adverse effects of risperidone on eye movement activity: A comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Neuropsychopharmacology 1997; 16:217-228.

Bertz RJ*, Kroboth PD, Kroboth FJ, Reynolds IJ, Salek FS*, Wright CE, Smith RB. Alprazolam in Elderly and Young Men. Sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther 1997; 281:1317-1329.

McAuley JW*, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: A review and more experience. Pharmacother 1996; 16:453-457.

Schwinghammer TL, Kroboth PD, Szajna JM, Dudjak LA, Brown FH. Documentation of interventions on a multidisciplinary health care team. Continuing Education Series. Pharmacy & Managed Care 1995; 3: 8-12. (Not peer reviewed).

Bertz RJ*, Kroboth PD, Reynolds IJ. Effect of neuroactive steroids on [3H]flumazenil binding to the GABAA receptor complex in vitro. Neuropharmacology 1995;34:1169-1175.

Greene D, Salazar DE, Dockens RC, Kroboth PD, Barbhaiya R. Coadministration of nefazodone and benzodiazepines: IV. Pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995; 15:409-416.

Barbhaiya RH, Shukla UA, Kroboth PD, Greene D. Coadministration of nefazodone and benzodiazepines: II. Pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15:320-326.

Kroboth PD, McAuley JW*, Kroboth FJ, Bertz RJ*, Rosanske T, Smith RB. Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J Clin Psychopharmacol 1995; 15:259-262.

Derry CL*, Kroboth PD, Pittenger A*, Kroboth FJ, Corey SE, Smith RB. Pharmacodynamics of triazolam after two intermittent doses in obese and normal weight subjects. J Clin Psychopharmacol 1995; 15:197-205.

Kroboth PD, McAuley JW*, Derry CL*. Time-dependent sensitization to triazolam- An observation in three studies. J Clin Psychopharmacol 1995; 15:192-196.

McAuley JW*, Reynolds IJ, Kroboth FJ, Smith RB, Kroboth PD. Orally administered progesterone enhances sensitivity to triazolam in post-menopausal women. J Clin Psychopharmacol 1995; 15:3-11.

Kroboth PD, Bertz RJ*, Smith RB. Acute tolerance to triazolam during continuous and step infusions: Estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993; 264:1047-1055.

McAuley JW*, Kroboth PD, Stiff DD, Reynolds IJ. Modulation of [3H]flunitrazepam binding by natural and synthetic progestational agents. Pharmacol Biochem Behavior 1993; 45:77-83.

Watling SM, Engelhardt JM, Kondrotas RJ, Gal P, Kroboth PD, Smith H, Johnson MK. Comparison of intranasal versus intravenous verapamil bioavailability. Int J Clin Pharmacol Therapy Toxicol 1993; 31:100-104.

Schmith VD*, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther 1992; 51:533-540.

Kroboth PD, Smith RB. Basic Bibliographies: Pharmacodynamics - 1991. Hospital Pharmacy 1991; 26:157. (Invited bibliography).

Kroboth PD, Schmith VD*, Smith RB. Pharmacodynamic Modeling: Application to new drug development. Clin Pharmacokin 1991; 20:91-98. (Invited paper)

Schmith VD*, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. I. Pharmacokinetics. J Clin Pharmacol 1991; 31:571-579.

Schmith VD*, Cox S, Zemaitis MA, Kroboth PD. A new HPLC method for the determination of alprazolam and its metabolites in serum; instability of 4-hydroxyalprazolam. J Chromatog Biomed Applications 1991; 568:253-260.

Kroboth PD, Maxwell RA*, Fleishaker JC, VanThiel DH, Smith RB. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects. J Clin Pharmacol 1991; 31:580-586.

Kroboth PD, McAuley JW*, Smith RB. Alprazolam in the elderly: pharmacokinetics and dynamics during multiple dosing. Psychopharmacology 1990; 100:477-484.

Garzone PD*, Kroboth PD. The pharmacokinetics of the newer benzodiazepines. Clin Pharmacokin 1989; 16:337-364. (Invited paper)

Kroboth PD, Smith RB. Relationship of triazolam clearance to alpha-1 acid glycoprotein concentrations. J Clin Psychopharmacol 1989; 9:380-381.

Kroboth PD, Schwinghammer TL. Modeling. In Controversy III: To Model or Not to Model. J Clin Pharmacol 1988; 28:879-888. (Invited paper)

Kroboth PD. (Book review) Guarino RA, editor. New drug approval process: clinical and regulatory management. Am Jour Pharmaceutical Educ 1988; 52:211. (Not peer reviewed)

Schwinghammer TL, Kroboth PD. Basic concepts in pharmacodynamic modeling. J Clin Pharmacol 1988; 28:388-394. (Invited paper)

Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects. Clin Pharmacol Ther 1988; 43:270-277.

Silver MR, Kroboth PD. Pentoxifylline in end stage renal disease: A case report. Drug Intell Clin Pharm 1987; 21:976-978.

Kroboth PD, Smith RB, VanThiel DH, Juhl RP. Nighttime dosing of triazolam in patients with liver disease and normal subjects: Kinetics and daytime effects. J Clin Pharmacol 1987; 27:555-560.

Smith RB, Kroboth PD, Varner PD. Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 1987; 27:971-979.

Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacol 1987; 93:105-112.

Smith RB, Kroboth PD, Juhl RP. An academic-industrial center for pharmacodynamic research. Am Jour Pharmaceutical Educ 1986; 50:472-474 and Drug Intell Clin Pharmacy 1987; 21:127-129. (Invited paper, published as complete symposium proceedings in two journals.)

Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertility & Sterility1986; 26:120-124.

Cox SR, Kroboth PD, Anderson PH, Smith RB. Mechanism for the interaction between triazolam and cimetidine. Biopharm Drug Disp 1986; 7:567-575.

Smith RB, Kroboth PD, Phillips JP. Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. J Clin Pharmacol 1986; 26:120-124.

Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985; 38:525-532.

Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP. Effects of end-stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol 1985; 19:839-842.

Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. Clin Pharmacol Ther 1985; 37:453-459.

Kroboth PD. Hearing loss and erythromycin pharmacokinetics in patients receiving hemodialysis. Arch Int Med 1984; 144:419-420. (letter)

Stoehr GP, Kroboth PD, Juhl RP, Wender DL, Phillips JP, Smith RB. Effect of oral contraceptive use on triazolam, temazepam, alprazolam and lorazepam kinetics. Clin Pharmacol Ther 1984; 36:683-690.

Smith RB, Kroboth PD, Phillips JP, VanderLugt J, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacol 1984; 84:452-456.

Juhl RP, Daugherty VM*, Kroboth PD. Incidence of next-day amnesia caused by flurazepam hydrochloride and triazolam. Clin Pharm 1984; 3:622-625.

Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, Juhl RP. Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration. Clin Pharmacol Ther 1984; 36:379-383.

Kroboth PD, Mitchum K, Puschett JB. Use of procainamide in continuous ambulatory peritoneal dialysis. Amer J Kidney Dis 1984; 4:78-79.

Greenberg A, Piraino BH, Kroboth PD, Weiss J. Severe theophylline toxicity: Role of conservative measures, newer antiarrhythmics and charcoal hemoperfusion. Amer J Med 1984; 76:854-860.

Kroboth PD, Juhl RP. New drug evaluations: Triazolam (Halcion-The Upjohn Company). Drug Intell Clin Pharm 1983; 17:495-500.

Kroboth FJ, Kroboth PD, Logan T. Quinidine - anticonvulsant interaction. N Engl J Med 1983; 17:495-500. (Letter)

Kroboth PD, McNeil MA, Kreeger A, Dominguez J, Rault R. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch of Intern Med 1983; 143:1263-1265.

Kroboth PD, Kroboth FJ. Pharmacologic therapy in cardiopulmonary resuscitation. US Pharm 1982; 7:112-116.

Kroboth PD, Brown A, Lyon JA, Kroboth FJ, Juhl RP. Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver disease subjects. Antimicrob Agents Chemother 1982; 21:135-140.

Fischer JM, Kroboth PD. Update: Tricyclic anti-depressant therapy. US Pharm 1980; 5:33-44.

Kroboth PD, Schwinghammer TL. Hepatotoxicity and erythromycin. Drug Intell Clin Pharm 1980; 14:627-628.